Genentech Provides Update on Tecentriq US Indication for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer

Genentech announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq® in combination with chemotherapy for the treatment of adults with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1, as determined by a US FDA-approved test.